Toggle Health Problems and D

2X more Parkinson's disease if modified vitamin D receptor genes – meta-analysis Aug 2014

Vitamin D receptor gene polymorphisms and the risk of Parkinson's disease.

Neurol Sci. 2014 Aug 29. [Epub ahead of print]
Chunlei Li (1); Huiping Qi (2); Shuqin Wei (3); Le Wang (4); Xiaoxue Fan (4); Shurong Duan (4)
Sheng Bi bisheng13224510036 at 163.com (4)
1. Department of Rehabilitation, The First Affiliated Hospital, Harbin Medical University, 150001, Harbin, China
2. Department of Neurology, The Fourth Affiliated Hospital, Harbin Medical University, 150001, Harbin, China
3. Saint-Justine Research Center, University of Montreal, Montreal, Canada
4. Department of Neurology, The First Affiliated Hospital, Harbin Medical University, 150001, Harbin, China

Reminder about Vitamin D Receptor

A vitamin D blood test can tell you that you have a high level of vitamin D, but the Vitamin D receptor gene modifications will reduce the efficiency of getting vitamin D to the cells.

499 studies in Vitamin D Receptor category

Vitamin D tests cannot detect Vitamin D Receptor (VDR) problems
A poor VDR restricts Vitamin D from getting in the cells

See also: 47 studies in the Resveratrol category

It appears that 30% of the population have a poor VDR (40% of the Obese )
Several diseases protect themselves by deactivating the Vitamin D receptor. Example: Breast Cancer
- - - - - - - -
The Vitamin D Receptor is associated with many health problems

Health problems include: Autoimmune (18 studies), Breast Cancer (20 studies), Colon Cancer (13 studies), Cardiovascular (23 studies), Cognition (16 studies), Diabetes (24 studies), Hypertension (9 studies), Infant (21 studies), Lupus (6 studies), Metabolic Syndrome (4 studies), Mortality (4 studies), Multiple Sclerosis (11 studies), Obesity (16 studies), Pregnancy (24 studies), Rheumatoid Arthritis (10 studies), TB (8 studies), VIRUS (34 studies),   Click here for details
Some health problems, such as Breast Cancer, Diabetes, and COVID protect themselves by reducing VDR activation

55 health problems associated with poor VDR

A poor VDR is associated with the risk of 55 health problems  click here for details
The risk of 48 diseases at least double with poor VDR as of Jan 2023  click here for details
Some health problem, such as Breast Cancer reduce the VDR

VDR at-home test $29 - results not easily understood in 2016
There are hints that you may have inherited a poor VDR

How to increase VDR activation

Compensate for poor VDR by increasing one or more:

1) Vitamin D supplement  Sun
Ultraviolet -B
Vitamin D in the blood
and thus in the cells
2) MagnesiumVitamin D in the blood
 AND in the cells
3) Omega-3 Vitamin D in the cells
4) Resveratrol Vitamin D Receptor
5) Intense exercise Vitamin D Receptor
6) Get prescription for VDR activator
   paricalcitol, maxacalcitol?
Vitamin D Receptor
7) Quercetin (flavonoid) Vitamin D Receptor
8) Zinc is in the VDRVitamin D Receptor
9) BoronVitamin D Receptor ?,
10) Essential oils e.g. ginger, curcuminVitamin D Receptor
11) ProgesteroneVitamin D Receptor
12) Infrequent high concentration Vitamin D
Increases the concentration gradient
Vitamin D Receptor
13) Sulfroaphane and perhaps sulfurVitamin D Receptor
14)Butyrate especially gutVitamin D Receptor

Note: If you are not feeling enough benefit from Vitamin D, you might try increasing VDR activation. You might feel the benefit within days of adding one or more of the above

Far healthier and stronger at age 72 due to supplements Includes 6 supplements that help the VDR
Pages listed in BOTH the categories VDR and PD

The effect of vitamin D receptor (VDR) gene polymorphisms on Parkinson's disease (PD) has recently gained interest. However, evidence on this relationship is controversial. We searched PubMed, EMBASE and the Cochrane Library database targeted all studies that evaluated VDR gene polymorphisms and PD up to April 2,014. A meta-analysis was conducted on the association between VDR ApaI, BsmI, TaqI and FokI polymorphisms and PD using (1) allelic contrast, (2) dominant, (3) recessive, and (4) additive models.

A total of five relevant studies involving PD patients (n = 1,266) and controls (n = 1,649) were included in the analysis. There was a significant association between FokI polymorphism and PD.
In the pooled allelic analysis, the

  • F allele was associated with increased risk of PD (OR 1.41, 95 % CI 1.14-1.75).

In the genotype analysis,

  • FF + Ff versus ff showed a significant association with PD in the dominant model (OR 2.32, 95 % CI 1.49-3.61, P = 0.0002).

FF versus ff showed a significant association with PD in the additive model (OR 2.45, 95 % CI 1.52-3.93, P = 0.0002).
There was also a statistically significant association between VDR BsmI polymorphisms in the recessive model,

  • BB versus Bb + bb showed a significant increased risk of PD (OR 1.37, 95 % CI 1.01-1.87, P = 0.04).

No significant associations were observed between VDR ApaI and TaqI polymorphisms and PD.

To sum up, VDR BsmI and FokI polymorphisms were associated with increased risk of PD.

PMID: 25169913

Publisher wants $45 for the PDF


  1. Thomas B, Beal MF (2007) Parkinson’s disease. Hum Mol Genet 16(2):R183–R194 CrossRef
  2. Hancock DB, Martin ER, Vance JM, Scott WK (2008) Nitric oxide synthase genes and their interactions with environmental factors in Parkinson’s disease. Neurogenetics 9(4):249–262 CrossRef
  3. Liu GJ, Feng RN, Luo C, Bi S (2010) Lack of association between interleukin-1 alpha, beta polymorphisms and Parkinson’s disease. Neurosci Lett 480(2):158–161 CrossRef
  4. McCulloch CC, Kay DM, Factor SA, Samii A, Nutt JG, Higgins DS, Griffith A, Roberts JW, Leis BC, Montimurro JS et al (2008) Exploring gene-environment interactions in Parkinson’s disease. Hum Genet 123(3):257–265 CrossRef
  5. Mizuta I, Tsunoda T, Satake W, Nakabayashi Y, Watanabe M, Takeda A, Hasegawa K, Nakashima K, Yamamoto M, Hattori N et al (2008) Calbindin 1, fibroblast growth factor 20, and alpha-synuclein in sporadic Parkinson’s disease. Hum Genet 124(1):89–94 CrossRef
  6. van der Walt JM, Noureddine MA, Kittappa R, Hauser MA, Scott WK, McKay R, Zhang F, Stajich JM, Fujiwara K, Scott BL et al (2004) Martin, Fibroblast growth factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson disease. Am J Hum Genet 74(6):1121–1127 CrossRef
  7. Evatt ML, Delong MR, Khazai N, Rosen A, Triche S, Tangpricha V (2008) Prevalence of vitamin d insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol 65(10):1348–1352
  8. Knekt P, Kilkkinen A, Rissanen H, Marniemi J, Sääksjärvi K, Heliövaara M (2010) Serum vitamin D and the risk of Parkinson disease. Arch Neurol 67(7):808–811
  9. Smolders J, Peelen E, Thewissen M, Menheere P, Tervaert JW, Hupperts R, Damoiseaux J (2009) The relevance of vitamin D receptor gene polymorphisms for vitamin D research in multiple sclerosis. Autoimmun Rev 8(7):621–626 CrossRef
  10. Garcion E, Wion-Barbot N, Montero-Menei CN, Berger F, Wion D (2002) New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab 13(3):100–105 CrossRef
  11. Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ (2005) Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat 29(1):21–30 CrossRef
  12. Lambrinoudaki I, Patikas E, Kaparos G, Armeni E, Rizos D, Thoda P, Alexandrou A, Antoniou A, Tsivgoulis G, Gatzonis S et al (2013) Vitamin D receptor Bsm1 polymorphism, calcium metabolism and bone mineral density in patients with multiple sclerosis: a pilot study. Neurol Sci 34(8):1433–1439 CrossRef
  13. Wang L, Hara K, Van Baaren JM, Price JC, Beecham GW, Gallins PJ, Whitehead PL, Wang G, Lu C, Slifer MA et al (2012) Vitamin D receptor and Alzheimer’s disease: a genetic and functional study. Neurobiol Aging 33(8):1844.e1–1844.e9 CrossRef
  14. Butler MW, Burt A, Edwards TL, Zuchner S, Scott WK, Martin ER, Vance JM, Wang L (2011) Vitamin D receptor gene as a candidate gene for Parkinson disease. Ann Hum Genet 75(2):201–210 CrossRef
  15. Lv Z, Tang B, Sun Q, Yan X, Guo J (2013) Association study between vitamin d receptor gene polymorphisms and patients with Parkinson disease in Chinese Han population. Int J Neurosci 123(1):60–64 CrossRef
  16. Suzuki M, Yoshioka M, Hashimoto M, Murakami M, Noya M, Takahashi D, Urashima M (2013) Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease. Am J Clin Nutr 97(5):1004–1013 CrossRef
  17. Zhang ZT, He YC, Ma XJ, Li DY, Lu GC (2014) Association between vitamin D receptor gene polymorphisms and susceptibility to Parkinson’s disease : a meta-analysis. Neurosci Lett 578(2):122–127 CrossRef
  18. Lee YH, Kim JH, Song GG (2014) Vitamin D receptor polymorphisms and susceptibility to Parkinson’s disease and Alzheimer’s disease: a meta-analysis. Neurol Sci. doi:10.1007/s10072-014-1868-4 Epub ahead of print
  19. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta- analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283(15):2008–2012 CrossRef
  20. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17(5):427–442 CrossRef
  21. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23(15):2129–2170 CrossRef
  22. Duckitt K, Harrington D (2005) Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 330(7491):565 CrossRef
  23. Han X, Xue L, Li Y, Chen B, Xie A (2012) Vitamin D receptor gene polymorphism and its association with Parkinson’s disease in Chinese Han population. Neurosci Lett 525(1):29–33 CrossRef
  24. Kim JS, Kim YI, Song C, Yoon I, Park JW, Choi YB, Kim HT, Lee KS (2005) Association of vitamin D receptor gene polymorphism and Parkinson’s disease in Koreans. J Korean Med Sci 20(3):495–498 CrossRef
  25. Lin CH, Chen KH, Chen ML, Lin HI, Wu RM (2014) Vitamin D receptor genetic variants and Parkinson’s disease in a Taiwanese population. Neurobiol Aging 35(5):1212.e11–1212.e13 CrossRef
  26. Petersen MS, Bech S, Christiansen DH, Schmedes AV, Halling J (2014) The role of vitamin D levels and vitamin D receptor polymorphism on Parkinson’s disease in the Faroe Islands. Neurosci Lett 561:74–79 CrossRef
  27. Suzuki M, Yoshioka M, Hashimoto M, Murakami M, Kawasaki K, Noya M, Takahashi D, Urashima M (2012) 25-hydroxyvitamin D, vitamin D receptor gene polymorphisms, and severity of Parkinson’s disease. Mov Disord 27(2):264–271 CrossRef
  28. Török R, Török N, Szalardy L, Plangar I, Szolnoki Z, Somogyvari F, Vecsei L, Klivenyi P (2013) Association of vitamin D receptor gene polymorphisms and Parkinson’s disease in Hungarians. Neurosci Lett 551:70–74 CrossRef
  29. Allen PJ, Feigin A (2014) Gene-based therapies in Parkinson’s Disease. Neurotherapeutics 11(1):60–67 CrossRef
  30. Deluca HF, Cantorna MT (2001) Vitamin D: its role and uses in immunology. FASEB J 15(14):2579–2585Ref. 30 CrossRef
  31. Fang Y, van Meurs JB, d’Alesio A, Jhamai M, Zhao H, Rivadeneira F, Hofman A, van Leeuwen JP, Jehan F, Pols HA et al (2005) Promoter and 3′-untranslated-region haplotypes in the vitamin d receptor gene predispose to osteoporotic fracture: the rotterdam study. Am J Hum Genet 77(5):807–823 CrossRef
  32. Jurutka PW, Remus LS, Whitfield GK, Thompson PD, Hsieh JC, Zitzer H, Tavakkoli P, Galligan MA, Dang HT, Haussler CA et al (2000) the polymorphic n terminus in human vitamin d receptor isoforms influences transcriptional activity by modulating interaction with transcription factor iib. Mol Endocrinol 14(3):401–420 CrossRef
  33. Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP (2004) Genetics and biology of vitamin D receptor polymorphisms. Gene 338(2):143–156 CrossRef
  34. Jurutka PW, Whitfield GK, Hsieh JC, Thompson PD, Haussler CA, Haussler MR (2001) Molecular nature of the vitamin D receptor and its role in regulation of gene expression. Rev Endocr Metab Disord 2(2):203–216 CrossRef
  35. Calne DB, Snow BJ, Lee C (1992) Criteria for diagnosing Parkinson’s disease. Ann Neurol 32:S125–S127 CrossRef
  36. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184 CrossRef
  37. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ (1992) What features improve the accuracy of clinical diagnosis in Parkinson’s disease: a clinicopathologic study. Neurology 42(6):1142–1146 CrossRef